Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | SELP | P16109 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880710 | 0.92 | LGALS3 (0.52) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL23121472 | 0.83 | LGALS9 (0.51) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL21045068 | 0.81 | PTPN1 (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL12870306 | 0.80 | GAPDH (0.47) | PTPN1 | |
| SCHEMBL15483275 | 0.79 | LGALS3 (0.50) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL16689629 | 0.79 | TDP1 (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL17766500 | 0.79 | GAPDH (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL16673453 | 0.79 | TDP1 (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL18022557 | 0.79 | TDP1 (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL16673452 | 0.79 | TDP1 (0.49) | PTPN1LGALS9LGALS1LGALS3LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185881-A1 | Oligosaccharide Compounds | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185881-A1 | Oligosaccharide Compounds | BACE1, BACE2, ENGASE | PTPN1 2791/4885LGALS9 236/4885LGALS1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.